Pfizer Inc. said Thursday first-quarter earnings and sales fell due to the expiration of US exclusivity licenses for two key drugs that now face competition from generic versions.
Read full story

No Comments Yet - You can be the first to comment!

Sorry, comments for this entry are closed at this time.

Subscribe to RSS

Syndicate